Current and Future Perspectives of PDL1 PET and SPECT Imaging

IF 4.6 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Seminars in nuclear medicine Pub Date : 2024-11-01 DOI:10.1053/j.semnuclmed.2024.09.008

Indraja D. Dev MD , Ameya D. Puranik DNB , Baljinder Singh PhD , Vikas Prasad MD, PhD

{"title":"Current and Future Perspectives of PDL1 PET and SPECT Imaging","authors":"Indraja D. Dev MD , Ameya D. Puranik DNB , Baljinder Singh PhD , Vikas Prasad MD, PhD","doi":"10.1053/j.semnuclmed.2024.09.008","DOIUrl":null,"url":null,"abstract":"<div><div>Programmed Death 1 (PD1) and Programmed Death Ligand (PDL1) play a crucial role in tumor microenvironment by helping cancer cells evade innate immunity. Numerous inhibitor anticancer drugs targeting this interplay have been used in clinical practice and many more are in preclinical stage. These drugs have shown promising results in achieving good response and long-term clinical benefit, is routinely performed to identify patients who may benefit. However, there are major challenges associated with these immunohistochemistry tests which have opened the space for noninvasive imaging modalities using PD1 and PDL1 inhibitors labeled with either PET or SPECT radionuclides. These radiopharmaceuticals, although primarily developed for the field of immunotherapy, have great potential in expanding and optimizing the combination of radiopharmaceutical therapies with PD1-PDL1 targeting anticancer drugs. This review elaborates currently available PET and SPECT radiopharmaceuticals targeting PD1-PDL1 axis. It also explores the potential future role of newer targets which are being developed and tested in various preclinical studies.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 6","pages":"Pages 966-975"},"PeriodicalIF":4.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001299824000849","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Programmed Death 1 (PD1) and Programmed Death Ligand (PDL1) play a crucial role in tumor microenvironment by helping cancer cells evade innate immunity. Numerous inhibitor anticancer drugs targeting this interplay have been used in clinical practice and many more are in preclinical stage. These drugs have shown promising results in achieving good response and long-term clinical benefit, is routinely performed to identify patients who may benefit. However, there are major challenges associated with these immunohistochemistry tests which have opened the space for noninvasive imaging modalities using PD1 and PDL1 inhibitors labeled with either PET or SPECT radionuclides. These radiopharmaceuticals, although primarily developed for the field of immunotherapy, have great potential in expanding and optimizing the combination of radiopharmaceutical therapies with PD1-PDL1 targeting anticancer drugs. This review elaborates currently available PET and SPECT radiopharmaceuticals targeting PD1-PDL1 axis. It also explores the potential future role of newer targets which are being developed and tested in various preclinical studies.

查看原文本刊更多论文

PDL1 PET 和 SPECT 成像的当前和未来展望。

程序性死亡 1（PD1）和程序性死亡配体（PDL1）通过帮助癌细胞逃避先天免疫，在肿瘤微环境中发挥着至关重要的作用。许多针对这种相互作用的抑制剂抗癌药物已用于临床实践，还有更多药物处于临床前阶段。这些药物在获得良好反应和长期临床获益方面取得了可喜的成果。然而，这些免疫组化检测存在重大挑战，这为使用标记有 PET 或 SPECT 放射性核素的 PD1 和 PDL1 抑制剂的无创成像模式开辟了空间。这些放射性药物虽然主要是为免疫疗法领域开发的，但在扩大和优化放射性药物疗法与 PD1-PDL1 靶向抗癌药物的结合方面具有巨大潜力。本综述阐述了目前可用的以 PD1-PDL1 轴为靶点的 PET 和 SPECT 放射性药物。它还探讨了正在开发并在各种临床前研究中进行测试的新靶点在未来可能发挥的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in nuclear medicine 医学-核医学

CiteScore

9.80

自引率

6.10%

发文量

审稿时长

14 days

期刊介绍： Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.